276 related articles for article (PubMed ID: 35452692)
1. A third dose of the BNT162b2 mRNA vaccine significantly improves immune responses among liver transplant recipients.
Davidov Y; Indenbaum V; Tsaraf K; Cohen-Ezra O; Likhter M; Ben Yakov G; Halperin R; Levy I; Mor O; Agmon-Levin N; Afek A; Rahav G; Lustig Y; Ben Ari Z
J Hepatol; 2022 Sep; 77(3):702-709. PubMed ID: 35452692
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity and Adverse Effects of the 2-Dose BNT162b2 Messenger RNA Vaccine Among Liver Transplantation Recipients.
Davidov Y; Tsaraf K; Cohen-Ezra O; Likhter M; Ben Yakov G; Levy I; Levin EG; Lustig Y; Mor O; Rahav G; Ben Ari Z
Liver Transpl; 2022 Feb; 28(2):215-223. PubMed ID: 34767690
[TBL] [Abstract][Full Text] [Related]
3. Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients.
Rabinowich L; Grupper A; Baruch R; Ben-Yehoyada M; Halperin T; Turner D; Katchman E; Levi S; Houri I; Lubezky N; Shibolet O; Katchman H
J Hepatol; 2021 Aug; 75(2):435-438. PubMed ID: 33892006
[TBL] [Abstract][Full Text] [Related]
4. Past COVID-19 and immunosuppressive regimens affect the long-term response to anti-SARS-CoV-2 vaccination in liver transplant recipients.
Toniutto P; Falleti E; Cmet S; Cussigh A; Veneto L; Bitetto D; Fornasiere E; Fumolo E; Fabris C; Sartor A; Peressutti R; Curcio F; Regattin L; Grillone L
J Hepatol; 2022 Jul; 77(1):152-162. PubMed ID: 35283215
[TBL] [Abstract][Full Text] [Related]
5. Third dose of the BNT162b2 vaccine in heart transplant recipients: Immunogenicity and clinical experience.
Peled Y; Ram E; Lavee J; Segev A; Matezki S; Wieder-Finesod A; Halperin R; Mandelboim M; Indenbaum V; Levy I; Sternik L; Raanani E; Afek A; Kreiss Y; Lustig Y; Rahav G
J Heart Lung Transplant; 2022 Feb; 41(2):148-157. PubMed ID: 34565682
[TBL] [Abstract][Full Text] [Related]
6. Humoral Response to 2-dose BNT162b2 mRNA COVID-19 Vaccination in Liver Transplant Recipients.
Guarino M; Esposito I; Portella G; Cossiga V; Loperto I; Tortora R; Cennamo M; Capasso M; Terracciano D; Galeota Lanza A; Di Somma S; Picciotto FP; Morisco F;
Clin Gastroenterol Hepatol; 2022 Jul; 20(7):1534-1541.e4. PubMed ID: 35066136
[TBL] [Abstract][Full Text] [Related]
7. Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial.
Munro APS; Feng S; Janani L; Cornelius V; Aley PK; Babbage G; Baxter D; Bula M; Cathie K; Chatterjee K; Dodd K; Enever Y; Qureshi E; Goodman AL; Green CA; Harndahl L; Haughney J; Hicks A; van der Klaauw AA; Kanji N; Libri V; Llewelyn MJ; McGregor AC; Maallah M; Minassian AM; Moore P; Mughal M; Mujadidi YF; Holliday K; Osanlou O; Osanlou R; Owens DR; Pacurar M; Palfreeman A; Pan D; Rampling T; Regan K; Saich S; Bawa T; Saralaya D; Sharma S; Sheridan R; Thomson EC; Todd S; Twelves C; Read RC; Charlton S; Hallis B; Ramsay M; Andrews N; Lambe T; Nguyen-Van-Tam JS; Snape MD; Liu X; Faust SN;
Lancet Infect Dis; 2022 Aug; 22(8):1131-1141. PubMed ID: 35550261
[TBL] [Abstract][Full Text] [Related]
8. High Immune Response Rate to the Fourth Boost of the BNT162b2 Vaccine against the Omicron Variants of Concern among Liver Transplant Recipients.
Davidov Y; Indenbaum V; Atari N; Kliker L; Tsaraf K; Asraf K; Cohen-Ezra O; Likhter M; Mor O; Doolman R; Weiss-Ottolenghi Y; Hod T; Afek A; Kreiss Y; Lustig Y; Regev-Yochay G; Mandelboim M; Ben-Ari Z
Viruses; 2022 Dec; 14(12):. PubMed ID: 36560773
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the Durability of the Immune Humoral Response to COVID-19 Vaccines in Patients With Cancer Undergoing Treatment or Who Received a Stem Cell Transplant.
Khan QJ; Bivona CR; Martin GA; Zhang J; Liu B; He J; Li KH; Nelson M; Williamson S; Doolittle GC; Sun W; Mudaranthakam DP; Streeter NR; McGuirk JP; Al-Rajabi R; Hoffmann M; Kasi A; Parikh RA; Zhong C; Mitchell L; Pessetto ZY; Pathak H; Ghosh A; LaFaver S; Sharma P; Godwin AK
JAMA Oncol; 2022 Jul; 8(7):1053-1058. PubMed ID: 35446353
[TBL] [Abstract][Full Text] [Related]
10. Poor humoral and T-cell response to two-dose SARS-CoV-2 messenger RNA vaccine BNT162b2 in cardiothoracic transplant recipients.
Schramm R; Costard-Jäckle A; Rivinius R; Fischer B; Müller B; Boeken U; Haneya A; Provaznik Z; Knabbe C; Gummert J
Clin Res Cardiol; 2021 Aug; 110(8):1142-1149. PubMed ID: 34241676
[TBL] [Abstract][Full Text] [Related]
11. Decline in Antibody Concentration 6 Months After Two Doses of SARS-CoV-2 BNT162b2 Vaccine in Solid Organ Transplant Recipients and Healthy Controls.
Hamm SR; Møller DL; Pérez-Alós L; Hansen CB; Pries-Heje MM; Heftdal LD; Hasselbalch RB; Fogh K; Madsen JR; Almagro Armenteros JJ; Knudsen AD; Poulsen JR; Frikke-Schmidt R; Hilsted LM; Sørensen E; Ostrowski SR; Harboe ZB; Perch M; Sørensen SS; Rasmussen A; Bundgaard H; Garred P; Iversen K; Nielsen SD
Front Immunol; 2022; 13():832501. PubMed ID: 35281023
[TBL] [Abstract][Full Text] [Related]
12. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
Front Immunol; 2022; 13():863554. PubMed ID: 35711445
[TBL] [Abstract][Full Text] [Related]
13. BNT162b2 Third Booster Dose Significantly Increases the Humoral Response Assessed by Both RBD IgG and Neutralizing Antibodies in Renal Transplant Recipients.
Hod T; Ben-David A; Olmer L; Scott N; Ghinea R; Mor E; Levy I; Indenbaum V; Lustig Y; Grossman E; Rahav G
Transpl Int; 2022; 35():10239. PubMed ID: 35387393
[No Abstract] [Full Text] [Related]
14. Infection or a third dose of mRNA vaccine elicits neutralizing antibody responses against SARS-CoV-2 in kidney transplant recipients.
Charmetant X; Espi M; Benotmane I; Barateau V; Heibel F; Buron F; Gautier-Vargas G; Delafosse M; Perrin P; Koenig A; Cognard N; Levi C; Gallais F; Manière L; Rossolillo P; Soulier E; Pierre F; Ovize A; Morelon E; Defrance T; Fafi-Kremer S; Caillard S; Thaunat O
Sci Transl Med; 2022 Mar; 14(636):eabl6141. PubMed ID: 35103481
[TBL] [Abstract][Full Text] [Related]
15. Humoral Response to the Third Dose of Sars-Cov-2 Vaccine in Kidney Transplant Recipients.
Grupper A; Rabinowich L; Ben-Yehoyada M; Katchman E; Baruch R; Freund T; Hagin D; Shlomo SB; Schwartz D; Schwartz IF; Shashar M; Bassat OK; Halperin T; Turner D; Saiag E; Goykhman Y; Shibolet O; Levy S; Houri I; Katchman H
Transplant Proc; 2022; 54(6):1439-1445. PubMed ID: 35346486
[TBL] [Abstract][Full Text] [Related]
16. Humoral and cellular response after BNT162b2 vaccine booster in hemodialysis patients and kidney transplant recipients.
De Cagna MR; Colucci V; Di Maggio A; Notaristefano N; Cianciotta F; Danza K; Salvatore F; Santoniccolo A; Lanzillotta SG; Perniola MA; Marangi AL; Morrone LFP; Tampoia M
Clin Exp Nephrol; 2023 May; 27(5):445-453. PubMed ID: 36795176
[TBL] [Abstract][Full Text] [Related]
17. Reduced Neutralization Efficacy against Omicron Variant after Third Boost of BNT162b2 Vaccine among Liver Transplant Recipients.
Davidov Y; Indenbaum V; Mandelboim M; Asraf K; Gonen T; Tsaraf K; Cohen-Ezra O; Likhter M; Nemet I; Kliker L; Mor O; Doolman R; Cohen C; Afek A; Kreiss Y; Regev-Yochay G; Lustig Y; Ben-Ari Z
Viruses; 2023 Jan; 15(1):. PubMed ID: 36680292
[TBL] [Abstract][Full Text] [Related]
18. Seroprevalence of SARS-CoV-2 spike IgG antibodies after the second BNT162b2 mRNA vaccine in Japanese kidney transplant recipients.
Hamaya T; Hatakeyama S; Yoneyama T; Tobisawa Y; Kodama H; Fujita T; Murakami R; Fujita N; Okamoto T; Yamamoto H; Yoneyama T; Hashimoto Y; Saitoh H; Narumi S; Tomita H; Ohyama C
Sci Rep; 2022 Apr; 12(1):5876. PubMed ID: 35393481
[TBL] [Abstract][Full Text] [Related]
19. Humoral and cellular immune responses to the SARS-CoV-2 BNT162b2 vaccine among a cohort of solid organ transplant recipients and healthy controls.
Yanis A; Haddadin Z; Spieker AJ; Waqfi D; Rankin DA; Talj R; Thomas L; Birdwell KA; Ezzell L; Blair M; Eason J; Varjabedian R; Warren CM; Nochowicz CH; Olson EC; Simmons JD; Yoder S; Guy M; Thomsen I; Chappell JD; Kalams SA; Halasa NB
Transpl Infect Dis; 2022 Feb; 24(1):e13772. PubMed ID: 34905653
[TBL] [Abstract][Full Text] [Related]
20. Differences in Antibody Responses Between an Inactivated SARS-CoV-2 Vaccine and the BNT162b2 mRNA Vaccine in Solid-Organ Transplant Recipients.
Erol Ç; Yanık Yalçın T; Sarı N; Bayraktar N; Ayvazoğlu Soy E; Yavuz Çolak M; Azap Ö; Arslan H; Haberal M
Exp Clin Transplant; 2021 Dec; 19(12):1334-1340. PubMed ID: 34951350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
